Medherant Builds Senior Exec Team
UK transdermal drug delivery firm Medherant is expanding its top management team with a number of new senior executive appointments, including a new chief operating officer and chief financial officer.
You may also be interested in...
Endo still sees significant potential in Vasostrict despite the onset of competition. Meanwhile, the firm says it is focusing on “optimizing” its generics business.
The new EU regulation on increasing powers of the European Medicines Agency in future health crises applies as of 1 March; it controversially sees the agency become more involved in device oversight.
Pivotal data presented at the ASCO GI meeting in liver and biliary tract cancers could add a couple of billion dollars to Imfinzi’s sales and breathe new life into the CTL4 inhibitor tremelimumab.